Posted by Michael Wonder on 24 Jun 2020
Looking back, UK patients unhappy with adalimumab biosimilar switch
24 June 2020 - The UK results show how challenging switching to a biosimilar can be, according to patient groups.
What do UK patients think about the process and communication used to switch to adalimumab biosimilars by the National Health Service and the local home care trusts?
According to a study presented at the European Hematology Association’s 25th Annual Congress, EHA25 Virtual, not very much.
